Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss
Diabetes · 01.06.2026 · 75 (6) · 938-950
DOI: 10.2337/db25-0466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, online erschienen am 01.04.2026. Verfasst von Nadejda Bozadjieva-Kramer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Service, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Bile Acids and Salts, Weight Loss, Bone and Bones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Dietary, surgical, and pharmacological methods can effectively reduce body weight; however, rapid weight loss can also be accompanied by a loss of lean mass. Previously, we found that intestinal fibroblast growth factor 15 (FGF15; mouse ortholog of human FGF19) protects against lean mass loss after sleeve gastrectomy in mice and that circulating FGF19 predicts lean mass retention after very-low-energy diets in humans. We investigated the regulatory functions of intestine-derived FGF15 in lean and bone mass, glucose tolerance, and changes in bile acid and lipid parameters after weight loss in mice. Rapid weight loss was induced either by transitioning high-fat diet–fed intestine-specific FGF15–knockout and control mice to standard chow for 25 days or by administering daily semaglutide. Semaglutide decreased body weight, fat mass, and lean mass, all of which returned to baseline levels after treatment cessation. Lean mass was not preserved during dietary intervention in mice lacking FGF15, whereas semaglutide decreased lean mass irrespective of FGF15. Dietary intervention reduced hepatic triglyceride levels more efficiently, whereas greater improvement in glucose tolerance was observed with semaglutide. Semaglutide modulated shifts in bile acid composition, with particularly pronounced changes seen in the absence of FGF15. These data indicate that multiple factors, including intervention strategy and dietary context, modulate gut–liver and muscle communication and preservation of lean mass. Article Highlights We evaluated the role of intestinal fibroblast growth factor 15 (FGF15) in regulating lean mass, glucose tolerance, bile acid, and lipid profiles after diet-induced compared with semaglutide-induced weight loss in mice. Mice lacking FGF15 lost more lean mass during dietary intervention, whereas semaglutide decreased lean mass irrespective of FGF15; dietary intervention reduced hepatic triglyceride levels more efficiently, whereas greater improvement in glucose tolerance and elevated cecal bile acid levels were observed with semaglutide; and loss of FGF15 altered bile acid levels, whereas semaglutide treatment further regulated these levels in both genotypes, with particularly pronounced changes observed in the absence of FGF15. Weight-loss intervention strategy and dietary context modulate gut–liver and muscle communication and preservation of lean mass.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Service, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI.
- Department of Surgery, University of Michigan, Ann Arbor, MI.
- Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI.
- Center for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME.
- Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
ORCID-Profile: Nadejda Bozadjieva-Kramer, Ormond A MacDougald, Randy J Seeley
Förderung
- NIDDK NIH HHS
- NIH HHS
- NCATS NIH HHS
- U.S. Department of Veterans Affairs
- NIGMS NIH HHS
- BLRD VA
- CSRD VA
- National Institutes of Health
Zitieren
APA
Bozadjieva-Kramer, N., McMahon, G., Li, Z., Wean, J., Shin, J. H., Myronovych, A., O'Rourke, R. W., MacDougald, O. A., & Seeley, R. J. (2026). Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss. Diabetes, 75(6), 938-950. https://doi.org/10.2337/db25-0466
Vancouver
Bozadjieva-Kramer N, McMahon G, Li Z, Wean J, Shin JH, Myronovych A, et al. Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss. Diabetes. 2026;75(6):938-950. doi:10.2337/db25-0466
BibTeX
@article{BozadjievaKramer2026,
author = {Bozadjieva-Kramer, Nadejda and McMahon, Garrett and Li, Ziru and Wean, Jordan and Shin, Jae Hoon and Myronovych, Andriy and O'Rourke, Robert W and MacDougald, Ormond A and Seeley, Randy J},
title = {Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {6},
pages = {938--950},
doi = {10.2337/db25-0466}
}
EUVIMED